找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Indolent Lymphomas; Martin Dreyling,Marco Ladetto Book 2021 Springer Nature Switzerland AG 2021 Indolent Lymphomas.Nodal marginal Zone Lym

[复制链接]
楼主: hector
发表于 2025-3-28 15:45:40 | 显示全部楼层
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) accounts for up to 8% of all B-cell lymphomas. It displays unique clinical and pathological features and is associated with chronic infections including . (HP) and . (CP), as well as autoimmune diseases. MALT lymphoma is an indolent disease as reflected by a 10-year overall survival of 75–80%. In p
发表于 2025-3-28 22:46:17 | 显示全部楼层
Nodal Marginal Zone Lymphomaity in the lymphoma classifications since 1994 (REAL and WHO), the differential diagnosis with other lymphomas is still imprecise and clinically requires the exclusion of extranodal or splenic involvement. With regard to treatment, prospective data are limited. Often, the guidelines refer to other i
发表于 2025-3-29 02:23:26 | 显示全部楼层
发表于 2025-3-29 05:24:17 | 显示全部楼层
发表于 2025-3-29 09:48:01 | 显示全部楼层
Mantle Cell Lymphoma to constitutive cyclin D1 overexpression. Despite high initial response rates, early relapses and rapid disease progression occur frequently after conventional chemotherapy, resulting in a median survival of only 3–5 years. However, 10–15% of patients present with a more indolent, chronic course. D
发表于 2025-3-29 12:49:42 | 显示全部楼层
Hairy Cell Leukemiais. The annual incidence of HCL is estimated to be 0.3 cases per 100,000. Diagnosis is made by a review of peripheral blood smear, flow cytometry, and bone marrow biopsy. The hairy cells have a typical pattern of B-cell antigen expression (CD19, CD20) and coexpression of CD11c, CD25, and CD103. Rece
发表于 2025-3-29 18:25:06 | 显示全部楼层
Treatment of Chronic Lymphocytic Leukemiaomplex process. While early stage and asymptomatic CLL should still undergo watch and wait, patients with advanced stage disease are required to undergo genetic testing of CLL in order to enable optimal selection of treatment. Patients with favorable genetic profile still qualify for frontline thera
发表于 2025-3-29 20:21:28 | 显示全部楼层
发表于 2025-3-30 00:44:22 | 显示全部楼层
发表于 2025-3-30 05:33:46 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-11 05:33
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表